8-K
filed March 31, 2025, 7:59 PM ET
ticker CNSP
CIK 0001729427
regulatory
confidence high
sentiment neutral
materiality 0.70
CNS Pharmaceuticals regains Nasdaq compliance; subject to one-year monitoring period
CNS Pharmaceuticals, Inc.
- Nasdaq letter dated March 31, 2025 confirms regained compliance with $1.00 bid price rule.
- Company subject to Mandatory Panel Monitor for one year from letter date.
- If noncompliance occurs within monitoring period, no additional cure period allowed; delisting process begins.
- Previous reverse stock splits (>250:1 cumulative) disqualified company from standard compliance period.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001683168-25-002140
- form_type
- 8-K
- ticker
- CNSP
- cik
- 0001729427
- company_name
- CNS Pharmaceuticals, Inc.
- filed_at
- 2025-03-31T23:59:59+00:00
- discovered_at
- 2026-05-14T18:03:04.644219+00:00
- generated_at
- 2026-05-24T01:59:24.831473+00:00
- sec_items
- ["8.01"]
- event_type
- regulatory
- sentiment
- neutral
- materiality_score
- 0.7
- calibrated_materiality_score
- 0.7
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001683168-25-002140
- json_url
- https://secwatch.observer/filing/0001683168-25-002140.json
- markdown_url
- https://secwatch.observer/filing/0001683168-25-002140.md
- text_url
- https://secwatch.observer/filing/0001683168-25-002140.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1729427/000168316825002140/0001683168-25-002140-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1729427/000168316825002140/cns_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
LESL
Leslie's regains Nasdaq compliance for minimum market value of publicly held shares
Leslie's, Inc.
June 1, 2026, 4:28 PM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
VYGR
FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's
Voyager Therapeutics, Inc.
June 1, 2026, 8:00 AM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
EXFY
Expensify regains Nasdaq minimum bid price compliance
Expensify, Inc.
May 29, 2026, 5:15 PM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
SLXN
Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted
Silexion Therapeutics Corp
May 29, 2026, 7:00 AM ET
regulatory
Items 3.03, 5.03, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
RR
Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing
RICHTECH ROBOTICS INC.
May 28, 2026, 4:49 PM ET
regulatory
Items 3.01, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
MNKD
FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29
MANNKIND CORP
May 28, 2026, 8:37 AM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
SNAL
Snail receives Nasdaq extension to Sept 22, 2026 to regain listing compliance
Snail, Inc.
May 27, 2026, 4:25 PM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
JAGX
Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027
Jaguar Health, Inc.
May 27, 2026, 9:10 AM ET
regulatory
Items 7.01, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.